{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:02:41Z","timestamp":1740106961517,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T00:00:00Z","timestamp":1574812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T00:00:00Z","timestamp":1574812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","award":["na"],"award-info":[{"award-number":["na"]}],"id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s00277-019-03842-4","type":"journal-article","created":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T09:04:42Z","timestamp":1574845482000},"page":"105-112","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial"],"prefix":"10.1007","volume":"99","author":[{"given":"Andrea","family":"K\u00fchnl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare","family":"Peckitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bijal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirit M.","family":"Ardeshna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian P.","family":"Macheta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Radford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rod","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shankaranarayana","family":"Paneesha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Barton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Chau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruwaida","family":"Begum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Valeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Wotherspoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imene","family":"Zerizer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,27]]},"reference":[{"key":"3842_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, van den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235\u2013242","journal-title":"N Engl J Med"},{"key":"3842_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Tr\u00fcmper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M, German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9:105\u2013116","journal-title":"Lancet Oncol"},{"key":"3842_CR3","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","volume":"12","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh M, Kuhnt E, Tr\u00fcmper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, L\u00f3pez-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N, MabThera International Trial (MInT) Group (2011) CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 12:1013\u20131022","journal-title":"Lancet Oncol"},{"issue":"Suppl 5","key":"3842_CR4","doi-asserted-by":"publisher","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","volume":"26","author":"H Tilly","year":"2015","unstructured":"Tilly H et al (2015) Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v116\u2013v125","journal-title":"Ann Oncol"},{"key":"3842_CR5","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Bri\u00e8re J, Moskowitz CH, Schmitz N (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28:4184\u20134190","journal-title":"J Clin Oncol"},{"key":"3842_CR6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/ejh.12416","volume":"94","author":"S Barton","year":"2015","unstructured":"Barton S, Hawkes EA, Cunningham D, Peckitt C, Chua S, Wotherspoon A, Attygalle A, Horwich A, Potter M, Ethell M, Dearden C, Gleeson M, Chau I (2015) Rituximab, gemcitabine, cisplatin and methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma. Eur J Haematol 94:219\u2013226","journal-title":"Eur J Haematol"},{"key":"3842_CR7","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","volume":"32","author":"M Crump","year":"2014","unstructured":"Crump M, Kuruvilla J, Couban S, MacDonald D, Kukreti V, Kouroukis CT, Rubinger M, Buckstein R, Imrie KR, Federico M, di Renzo N, Howson-Jan K, Baetz T, Kaizer L, Voralia M, Olney HJ, Turner AR, Sussman J, Hay AE, Djurfeldt MS, Meyer RM, Chen BE, Shepherd LE (2014) Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol 32:3490\u20133496","journal-title":"J Clin Oncol"},{"key":"3842_CR8","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1200\/JCO.2016.69.0198","volume":"35","author":"GW Van Imhoff","year":"2017","unstructured":"Van Imhoff GW et al (2017) Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study. J Clin Oncol 35:544\u2013551","journal-title":"J Clin Oncol"},{"key":"3842_CR9","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.bbmt.2006.12.452","volume":"13","author":"RE Lerner","year":"2007","unstructured":"Lerner RE, Thomas W, DeFor TE, Weisdorf DJ, Burns LJ (2007) The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin\u2019s lymphoma in second complete or partial remission. Biol Blood Marrow Transplant 13:486\u2013492","journal-title":"Biol Blood Marrow Transplant"},{"key":"3842_CR10","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.3324\/haematol.13440","volume":"93","author":"A Martin","year":"2008","unstructured":"Martin A et al (2008) R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL\/TAMO study. Haematologica 93:1829\u20131836","journal-title":"Haematologica"},{"key":"3842_CR11","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","volume":"26","author":"PH Wiernik","year":"2008","unstructured":"Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann TM (2008) Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma. J Clin Oncol 26:4952\u20134957","journal-title":"J Clin Oncol"},{"key":"3842_CR12","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","volume":"22","author":"TE Witzig","year":"2011","unstructured":"Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, Bouabdallah R, Haioun C, Tilly H, Guo P, Pietronigro D, Ervin-Haynes AL, Czuczman MS (2011) An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin\u2019s lymphoma. Ann Oncol 22:1622\u20131627","journal-title":"Ann Oncol"},{"key":"3842_CR13","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1158\/1078-0432.CCR-16-2818","volume":"23","author":"MS Czuczman","year":"2017","unstructured":"Czuczman MS, Trn\u011bn\u00fd M, Davies A, Rule S, Linton KM, Wagner-Johnston N, Gascoyne RD, Slack GW, Brousset P, Eberhard DA, Hernandez-Ilizaliturri FJ, Salles G, Witzig TE, Zinzani PL, Wright GW, Staudt LM, Yang Y, Williams PM, Lih CJ, Russo J, Thakurta A, Hagner P, Fustier P, Song D, Lewis ID (2017) A phase 2\/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator\u2019s choice in patients with relapsed or refractory diffuse large B-cell lymphoma. Clin Cancer Res 23:4127\u20134137","journal-title":"Clin Cancer Res"},{"key":"3842_CR14","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.clml.2011.02.001","volume":"11","author":"PL Zinzani","year":"2011","unstructured":"Zinzani PL et al (2011) Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk 11:462\u2013466","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3842_CR15","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1038\/leu.2013.95","volume":"27","author":"M Wang","year":"2013","unstructured":"Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L (2013) Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 27:1902\u20131909","journal-title":"Leukemia"},{"key":"3842_CR16","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/S1470-2045(14)70191-3","volume":"15","author":"U Vitolo","year":"2014","unstructured":"Vitolo U, Chiappella A, Franceschetti S, Carella AM, Baldi I, Inghirami G, Spina M, Pavone V, Ladetto M, Liberati AM, Molinari AL, Zinzani P, Salvi F, Fattori PP, Zaccaria A, Dreyling M, Botto B, Castellino A, Congiu A, Gaudiano M, Zanni M, Ciccone G, Gaidano G, Rossi G, Fondazione Italiana Linfomi (2014) Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol 15:730\u2013737","journal-title":"Lancet Oncol"},{"key":"3842_CR17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","volume":"33","author":"GS Nowakowski","year":"2015","unstructured":"Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE (2015) Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study. J Clin Oncol 33:251\u2013257","journal-title":"J Clin Oncol"},{"key":"3842_CR18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/bjh.13945","volume":"173","author":"A Mart\u00edn","year":"2016","unstructured":"Mart\u00edn A, Redondo AM, Dlouhy I, Salar A, Gonz\u00e1lez-Barca E, Canales M, Montes-Moreno S, Ocio EM, L\u00f3pez-Guillermo A, Caballero D, Spanish Group for Lymphomas and Autologous Bone Marrow (GELTAMO) (2016) Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group. Br J Haematol 173:245\u2013252","journal-title":"Br J Haematol"},{"key":"3842_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/bjh.12846","volume":"166","author":"T Feldman","year":"2014","unstructured":"Feldman T, Mato AR, Chow KF, Protomastro EA, Yannotti KM, Bhattacharyya P, Yang X, Donato ML, Rowley SD, Carini C, Valentinetti M, Smith J, Gadaleta G, Bejot C, Stives S, Timberg M, Kdiry S, Pecora AL, Beaven AW, Goy A (2014) Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse\/primary refractory diffuse large B-cell lymphoma. Br J Haematol 166:77\u201383","journal-title":"Br J Haematol"},{"key":"3842_CR20","doi-asserted-by":"publisher","first-page":"JCO.2014.59.536","DOI":"10.1200\/JCO.2014.59.5363","volume":"33","author":"JG Gribben","year":"2015","unstructured":"Gribben JG, Fowler N, Morschhauser F (2015) Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol 33:JCO.2014.59.5363","journal-title":"J Clin Oncol"},{"key":"3842_CR21","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","volume":"21","author":"Y Yang","year":"2012","unstructured":"Yang Y, Shaffer a 3rd, Emre NC, Ceribelli M, Zhang M, Wright G, Xiao W, Powell J, Platig J, Kohlhammer H, Young RM, Zhao H, Yang Y, Xu W, Buggy JJ, Balasubramanian S, Mathews LA, Shinn P, Guha R, Ferrer M, Thomas C, Waldmann TA, Staudt LM (2012) Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 21:723\u2013737","journal-title":"Cancer Cell"},{"key":"3842_CR22","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.1002\/cncr.26135","volume":"117","author":"FJ Hernandez-Ilizaliturri","year":"2011","unstructured":"Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR, Goy A, Witzig TE, Czuczman MS (2011) Higher response to lenalidomide in relapsed\/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 117:5058\u20135066","journal-title":"Cancer"},{"key":"3842_CR23","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1200\/JCO.2017.72.6984","volume":"35","author":"C Thieblemont","year":"2017","unstructured":"Thieblemont C et al (2017) Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. JCO 35:2473\u20132481","journal-title":"JCO"},{"key":"3842_CR24","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on Lymphoma (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579\u2013586","journal-title":"J Clin Oncol"},{"key":"3842_CR25","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","volume":"123","author":"DW Scott","year":"2014","unstructured":"Scott DW, Wright GW, Williams PM, Lih CJ, Walsh W, Jaffe ES, Rosenwald A, Campo E, Chan WC, Connors JM, Smeland EB, Mottok A, Braziel RM, Ott G, Delabie J, Tubbs RR, Cook JR, Weisenburger DD, Greiner TC, Glinsmann-Gibson BJ, Fu K, Staudt LM, Gascoyne RD, Rimsza LM (2014) Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin embedded tissue. Blood 123:1214\u20131217","journal-title":"Blood"},{"key":"3842_CR26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/bjh.12172","volume":"160","author":"LH Zhang","year":"2013","unstructured":"Zhang LH, Kosek J, Wang M, Heise C, Schafer PH, Chopra R (2013) Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol 160:487\u2013502","journal-title":"Br J Haematol"},{"key":"3842_CR27","doi-asserted-by":"crossref","unstructured":"Nowakowski GS, Hong F, Scott DW (2019) Addition of lenalidomide to R-CHOP (R2CHOP) improves outcome in newly diagnosed diffuse large B-cell lymphoma (DLBCL): first report of ECOG-ACRIN1412 a randomized phase 2 US Intergroup study of R2CHOP vs R-CHOP. Hematological Oncology 37\u201338","DOI":"10.1002\/hon.6_2629"},{"key":"3842_CR28","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/bmt.2008.82","volume":"41","author":"PB Johnston","year":"2008","unstructured":"Johnston PB, Wiseman GA, Micallef INM (2008) Positron emission tomography using F-18 fluorodeoxyglucose pre- and post-autologous stem cell transplant in non-Hodgkin\u2019s lymphoma. Bone Marrow Transplant 41:919\u2013925","journal-title":"Bone Marrow Transplant"},{"key":"3842_CR29","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1182\/blood-2014-10-606939","volume":"125","author":"CS Sauter","year":"2015","unstructured":"Sauter CS, Matasar MJ, Meikle J, Schoder H, Ulaner GA, Migliacci JC, Hilden P, Devlin SM, Zelenetz AD, Moskowitz CH (2015) Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Blood 125:2579\u20132581","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03842-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03842-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03842-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T14:08:56Z","timestamp":1609596536000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03842-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,27]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["3842"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03842-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2019,11,27]]},"assertion":[{"value":"9 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The missing ESM file was inserted.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}